ArticleJournal of neuroinflammation2019
CD147 as a key mediator of the spleen inflammatory response in mice after focal cerebral ischemia.
Article in Journal of neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Antler stem cells effectively alleviate the symptoms of cerebral ischemic injury via immunomodulation of the spleen.Cell death discovery · 2026Article
- Immunological Profile and Markers of Endothelial Dysfunction in Elderly Patients with Cognitive Impairments.International journal of molecular sciences · 2024Article
- Mechanisms of inflammation after ischemic stroke in brain-peripheral crosstalk.Frontiers in molecular neuroscience · 2024Review
- Imaging increased metabolism in the spinal cord in mice after middle cerebral artery occlusion.Photoacoustics · 2023Article
- The gastrointestinal-brain-microbiota axis: a promising therapeutic target for ischemic stroke.Frontiers in immunology · 2023Review
- Neuroprotective Effects of Chlorogenic Acid in a Mouse Model of Intracerebral Hemorrhage Associated with Reduced Extracellular Matrix Metalloproteinase Inducer.Biomolecules · 2022Article
- Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia.Journal of biomolecular structure & dynamics · 2022Article
- Extracellular matrix metalloproteinase inducer in brain ischemia and intracerebral hemorrhage.Frontiers in immunology · 2022Review
- The Disease-Modifying Role of Taurine and Its Therapeutic Potential in Coronavirus Disease 2019 (COVID-19).Advances in experimental medicine and biology · 2022Review
- Inflammation-relevant microbiome signature of the stroke brain, gut, spleen, and thymus and the impact of exercise.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Article
- The "Dialogue" Between Central and Peripheral Immunity After Ischemic Stroke: Focus on Spleen.Frontiers in immunology · 2021Review
- Targeting Brain-spleen Crosstalk After Stroke: New Insights Into Stroke Pathology and Treatment.Current neuropharmacology · 2021Review
- CD147 Aggravated Inflammatory Bowel Disease by Triggering NF-BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe splenic inflammatory response after cerebral ischemia has been implicated in secondary brain injury. We have recently reported that CD147 plays an important role in driving brain inflammation after ischemic stroke. In this study, we hypothesized that CD147 may play a role in the splenic inflammatory response after cerebral ischemia.
methodsTransient (60 min) middle cerebral artery occlusion was induced in wild-type mice treated with an anti-CD147 antibody (αCD147) 1 h before ischemia onset. The splenic inflammatory response was evaluated at 4 and 24 h, representing the peak and early stage of splenic inflammatory activation in this model. Changes in mRNA and protein expression of CD147 and inflammatory markers were measured using RT-qPCR and western blot, respectively. Immune cells in the spleen and brain were measured using flow cytometry.
resultsCD147 expression was rapidly upregulated in the spleen at 4 and 24 h after ischemia onset. The splenic inflammatory response induced by cerebral ischemia was inhibited by αCD147 treatment as demonstrated by the reduced expression of cytokines (TNFα, IL-6, IL-1β) and monocyte chemoattractant protein-1 (MCP-1) in the spleen at 4 and 24 h after ischemia onset. Furthermore, reduced expression of Ly-6C and CCR2 coincided with a decrease in the number of Ly-6C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.